Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial

被引：0
作者：
Sophie Postel-Vinay
Juan Coves
Matthieu Texier
Mihaela Aldea
Anas Gazzah
Manuel Dómine
David Planchard
Ramon De Las Peñas
Ma Angeles Sala Gonzalez
Santiago Viteri
Javier Perez
Ana Laura Ortega
Teresa Moran
Carlos Camps
Ana Lopez-Martin
Mariano Provencio
Jean-Charles Soria
Benjamin Besse
Bartomeu Massuti
Rafael Rosell
机构：
[1] DITEP,Drug Development Department
[2] Gustave Roussy,Medical Oncology Department
[3] ERC StG group,Biostatistics Department
[4] Inserm Unit U981,Department of Medical Oncology
[5] Gustave Roussy,Medical Oncology Department
[6] University College of London,Faculty of Medicine
[7] Cancer Institute,Medical Oncology Department
[8] Hospital Son Llátzer,Medical Oncology Department
[9] Gustave Roussy,Instituto Oncológico Dr. Rosell
[10] Thoracic tumor board and International Cancer for Thoracic Cancers (CICT),Medical Oncology Department
[11] Hospital Universitario Fundación Jiménez Díaz,Medical Oncology Department
[12] IIS-FJD,Institut Català d’Oncologia Badalona
[13] Paris-Saclay University,Hospital General Universitario de Valencia, Medical Oncology Department; TRIAL Mixed Unit
[14] Consorcio Hospitalario Provincial de Castellón,Medical Oncology Department, Hospital Universitario Puerta de Hierro
[15] Hospital Universitario Basurto,Medical Oncology Department
[16] Hospital Universitario Dexeus,undefined
[17] Grupo Quirón Salud,undefined
[18] Hospital Virgen de los Lirios de Alcoy,undefined
[19] Hospital Universitario de Jaén,undefined
[20] Hospital Universitari Germans Trias i Pujol,undefined
[21] Badalona; Badalona Applied Research Group in Oncology,undefined
[22] Centro Investigación Príncipe Felipe-Fundación Investigación Hospital General Universitario de Valencia,undefined
[23] Medical Oncology Department,undefined
[24] Hospital Universitario Severo Ochoa,undefined
[25] Universidad Autónoma Madrid,undefined
[26] IDIPHIM,undefined
[27] Hospital Universitario Dr. Balmis de Alicante,undefined
[28] Germans Trias i Pujol Research Institute and Hospital (IGTP),undefined
[29] Badalona; Translational Cancer Research Unit,undefined
[30] Instituto Oncológico Dr Rosell,undefined
[31] Dexeus University Hospital,undefined
来源：
British Journal of Cancer | 2024年 / 130卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：417 / 424
页数：7
相关论文
共 209 条
[1]  
Schiller JH(2002)Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N. Engl J Med 346 92-8
[2]  
Harrington D(2012)Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial Lancet Oncol 13 247-55
[3]  
Belani CP(2009)Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 1432-40
[4]  
Langer C(2014)Maintenance therapies for non-small cell lung cancer Front Oncol 4 213-8
[5]  
Sandler A(2017)PARP inhibitors: synthetic lethality in the clinic Science 355 1152-47
[6]  
Krook J(2019)A decade of clinical development of PARP inhibitors in perspective Ann Oncol 30 1437-25
[7]  
Paz-Ares L(2022)Veliparib plus carboplatin and paclitaxel versus investigator’s choice of standard chemotherapy in patients with advanced non-squamous non-small cell lung cancer Clin Lung Cancer 23 214-59
[8]  
de Marinis F(2020)The forefront of ovarian cancer therapy: update on PARP inhibitors Ann Oncol 31 1148-28
[9]  
Dediu M(2019)Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer N Engl J Med 381 2416-402
[10]  
Thomas M(2019)Niraparib in patients with newly diagnosed advanced ovarian cancer N Engl J Med 381 2391-27
12345678910